RESEARCH MONOGRAPH · KDC-MN-271

Tamoxifen

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 3 min read

Our opinion on this compound

89/100

Original SERM with sixty years of clinical history and still the reference compound for the class

Tamoxifen is one of those compounds where the clinical legacy is so dominant that the basic pharmacology gets undersold. ICI discovered it as part of the failed Imperial Chemical Industries fertility program in the 1960s, Arthur Walpole and Dora Richardson did the original work, and it became the prototype selective estrogen receptor modulator. The patient-years of human exposure across breast cancer treatment and prevention is in the tens of millions over five decades, which is a level of human safety data essentially no other endocrine compound matches.

The mechanism is well-mapped and more interesting than the textbook version. Tamoxifen is a triphenylethylene SERM with mixed agonist/antagonist activity depending on tissue context. In breast tissue it acts as an estrogen receptor antagonist via differential coactivator recruitment; in endometrium and bone it's more agonist-like. The selectivity is driven by tissue-specific coregulator expression and the conformational state of ER-alpha after tamoxifen binding, which differs from the conformation produced by estradiol.

The active metabolite story matters. The CYP2D6-mediated conversion to endoxifen (4-hydroxy-N-desmethyltamoxifen) is responsible for most of the antiestrogenic activity, which means CYP2D6 poor metabolizers and CYP2D6-inhibiting comedications meaningfully reduce efficacy. This was a big enough finding that endoxifen itself has been in clinical development. For research use the metabolite question is essential context.

What we like is the cleanness of the data. Multiple very large adjuvant trials (NSABP, EBCTCG meta-analyses), the long-tail prevention data, the bone and lipid data from the prevention trials. Effect sizes are real and reproducible. The endometrial cancer risk and venous thromboembolism risk are real and predictable.

For research-use contexts, tamoxifen is the standard reference SERM, and Cre-ERT2 inducible systems use 4-hydroxytamoxifen as the activating ligand across thousands of mouse genetics papers. The compound is everywhere in developmental biology and conditional knockout work.

Sourcing is excellent. Off-patent for decades, pharmacopoeial quality widely available, the citrate salt is the standard. Research-grade 4-hydroxytamoxifen for inducible-Cre work is a separate category with its own QC standards.

Workhorse with the underappreciated angle being how mechanistically rich the SERM concept is. Reliability is high, mechanism is textbook, safety is well-characterized.

Evidence: 95
Mechanism: 90
Reliability: 90
Safety: 80
Sourcing: 95
Value: 92
Signal: 80
Staying power: 90

Plain-language summary Intrigue 70 / 100

Tamoxifen (Nolvadex) is the foundational antiestrogen, FDA-approved in 1977 and one of the most-prescribed cancer drugs ever made. It is a selective estrogen receptor modulator (SERM): a blocker in breast tissue (the basis for hormone-receptor-positive breast cancer treatment and prevention) and a partial activator in bone, liver, and uterus. The active metabolite endoxifen, generated by the liver enzyme CYP2D6, is roughly a hundred times more potent than the parent drug, so people with low CYP2D6 activity may respond poorly. Off-label, it is widely used as post-cycle therapy by anabolic steroid users to restore natural testosterone production. Side effects include hot flashes and a small increase in endometrial cancer risk. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Selective estrogen receptor modulator (triphenylethylene)

A triphenylethylene SERM; the foundational antiestrogen for ER-positive breast cancer and an off-label tool for SARM/AAS post-cycle therapy.

Abstract

Tamoxifen ((Z)-2-[4-(1,2-diphenyl-1-butenyl)phenoxy]-N,N-dimethylethanamine; CAS 10540-29-1; molecular formula C26H29NO; molecular weight 371.51) is a triphenylethylene SERM developed at ICI Pharmaceuticals (now AstraZeneca) and approved by the FDA in 1977 under the trade name Nolvadex. The compound is a tissue-selective estrogen receptor modulator: antagonist in breast tissue (the basis for breast cancer indications) and partial agonist in bone, liver, and uterus. The active metabolite endoxifen (4-hydroxy-N-desmethyltamoxifen) generated via CYP2D6 is approximately 100-fold more potent than tamoxifen at ER binding and contributes substantially to clinical activity; CYP2D6 polymorphism affects clinical response. Plasma half-life is approximately 5 to 7 days for parent compound. Approved indications include adjuvant treatment of ER-positive breast cancer (premenopausal and postmenopausal), metastatic breast cancer, and breast cancer prevention in high-risk patients. Off-label use in male hypogonadism, gynecomastia treatment, and post-cycle therapy following SARM or anabolic steroid use is common. Adverse events include endometrial cancer (rare), thromboembolism, and hot flashes. Used as the canonical SERM in mechanism studies.

Mechanism of action

Triphenylethylene SERM with tissue-selective ER modulation: antagonist in breast, partial agonist in bone/uterus. Active metabolite endoxifen drives clinical activity. CYP2D6-dependent metabolism.

Reported research dose ranges

Clinical 10 to 40 mg in the published literature. PCT use commonly 20 to 40 mg. Rodent studies 1 to 10 mg/kg.

References

Jordan VC. Tamoxifen: a most unlikely pioneering medicine. Nat Rev Drug Discov 2003.
Goetz MP, et al. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat 2007.
Visvanathan K, et al. Use of pharmacologic interventions for breast cancer risk reduction. ASCO Clinical Practice Guideline 2019.

Read the full monograph

The full reference document is available as a research-use-only PDF download. Note: PDFs for newly added compounds may take a few hours to propagate after this article was published.

KDC-MN-271

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

Tamoxifen

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs